Denali Therapeutics Inc. (NASDAQ: DNLI) recently informed its shareholders of the status of its ongoing clinical trials. The company began trials of using DNL593 (PTV-PGRN) to treat patients with frontotemporal dementia, which resulted from genetic alterations in the brain. Additionally, Denali platforms create various accomplishments that advance other remarkable developments in the therapeutic area of the brain.
Denali Therapeutics partners with Takeda to market and sell the therapy
Denali Therapeutics has yet to release initial results from the first phase of the study. So, it recently started making plans to start the 2nd phase of trials before June 2022. To facilitate the study, the company has entered into a partnership with Takeda to sell and advertise the drug,
During the second phase of the study, the organization intends to inject participants with the FTD-GRN before June of this year. Brain impairment during dementia is characterized by specific shortages of progranulin and other hormones. Additionally, Denali has developed a mechanism that transmits the protein (PTV: PGRN), thus affecting the therapeutic standards set by the company.
The main purpose of the compound is to decrease and stop the ongoing spread of FTD-GRN by adding to intracellular or extracellular amounts of PGRN. During the announcement, Denali Therapeutics acknowledged that the trials are on track, making progress in the right direction.
Symptoms of frontotemporal dementia
Frontotemporal dementia is the most common form of dementia affecting patients under the age of 60. The spread of the disease differs from individual to individual; thus, the spread can become endemic.
Some of the symptoms of the disease include dramatic and sudden changes in personality, poor judgment, apathy, loss of self-awareness, increased dependency, erratic mood swings, forgetfulness and others.
The granulin gene is responsible for various roles, including that of transmitting proteins; thus, a decrease in the amounts mainly affects patients with many genetic abnormalities that lead to dementia. Unfortunately, there has been no reasonable cure since the discovery of the disease, hence the various developments.
It focuses on biotechnological advances combining them with distinct expertise in antiviral therapeutics. Its portfolio consists of an award-winning team of study and academic authors.